肺癌患者血清基质金属蛋白酶-9、内皮抑素、血管内皮生长因子的变化及其临床意义

Elevated serum levels of MMP-9 endostatin and VEGF in lung cancer and its clinical significance

目的测定肺癌患者血清基质金属蛋白酶-9(MMP-9)、内皮抑素(endostatin,ES)、血管内皮生长因子(VEGF)水平,探讨其在肺癌中的特异性及其与化疗的关系。方法应用酶联免疫吸附法(ELISA)测定3种因子在144例肺癌患者血清中的表达。结果肺癌患者血清MMP-9、ES、VEGF分别为(678．06±38．79)ng/ml、(124．90±3．33) ng/ml及(809．81±129．43)pg/ml,显著高于对照组的(90．07±13．55)ng/ml、(61．0±5．15)ng/ml及(368．68±5．82)pg/ml,以及肺良性病变者的(228．96±15．39)ng/ml、(91．43±4．44)ng/ml及(490．14±14．58)pg/ml(P＜0．001)；肺癌患者血清MMP-9、ES及VEGF水平与肿瘤组织类型、有无远处转移、临床分期及原发肿瘤大小相关(P＜0．05)；化疗后3种因子分别为(569．23±100．08)ng/ml、(141．36±14．51)ng/ml及(680．94±130．47)pg/ml,与化疗前的(726．28±94．11)ng/ml、(127．86±13．24)ng/ml及(1415．01±587．22)pg/ml相比有显著性差异(P＜0．001)；肺癌患者血清MMP-9与ES水平呈正相关(r= 0．260．P=0．012)。结论肺癌患者血清MMP-9、ES、VEGF水平明显升高,在肺癌的病理疾病过程中有特殊意义,可作为预测肺癌恶性度和治疗反应的良好指标。

Objective To study the relationship among serum levels of MMP-9, endostatin,VEGF and the clinical pathophysiological characteristics of lung cancer patients. Methods Serum levels of MMP-9, endostatin and VEGF were detected by ELISA method in 144 patients with lung cancer. Results The serum levels of MMP-9, endostatin and VEGF in lung cancer patients were significantly higher than those of patients with benign pulmonary diseases and healthy group （P〈0.001）.The serum levels of MMP-9, endostatin and VEGF in lung cancer patients were closely related to the histological classification,type of tumor, TNM-stages,size of tumor and distant metastasis（P〈0.05）. The changes of serum MMP-9, endo- statin and VEGF in lung cancer patients after chemotherapy were related to the effect of treatment （P〈0.001）. The serum level of MMP-9 of lung cancer patients was positively correlated with serum endostatin level in lung cancer patients （r= 0.260,P=-0.012）. Conclusions The serum level of MMP-9, endostatin and VEGF are elevated in patients with lung cancer suggesting that they may be used to evaluate the biological behavior of lung cancer.